Timothy D. Clay

St John Of God Subiaco Hospital
Subiaco, WA, AU 
St John Of God Subiaco Hospital
Subiaco, WA, AU 

Overview

Timothy Clay practices practicing medicine in Subiaco, Australia.

His clinical expertise encompasses Lung Cancer, Lung Adenocarcinoma, EGFR Positive Lung Cancer, and Small Cell Lung Cancer (SCLC).

He is actively involved in clinical research, co-authoring 36 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

St John of God Subiaco Hospital
Subiaco, WA 6008, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Biological
Study Phase: Phase 1
View 1 Less Clinical Trial

36 Total Publications

Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.
Journal: Future oncology (London, England)
Published: March 04, 2026

Frequently Asked Questions about Timothy D. Clay

Is Timothy D. Clay a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Timothy D. Clay is classified as an Experienced expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Timothy D. Clay participate in research or clinical trials?

Yes. Timothy D. Clay has published 36 articles and abstracts on conditions like Lung Cancer. You can view a list of Timothy D. Clay's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Clay's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile